|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
October 2007FeaturesEmployers 5 Things Employers Want to Know About BiologicsCan a determination of the value of biologics really be boiled down to a handful of issues? According to our sample of purchasers, the number of issues that really counts in the realm of biologics is just 5. Venture Capital Where VC Fears to TreadIn recent years, venture capitalists have been less willing to place bets on preclinical technologies. Major drug manufacturers, flush with cash but increasingly bereft of blockbusters, are stepping into the breach. So are established biotech companies. Here’s a look at how the changing sources and timing of investments are helping to shape biotech’s future. Diagnostics Biogenetic Tests Emerge From Their ChrysalisAs technology improves, barriers to payment are beginning to fall for costly diagnostic tests that may identify good candidates for even pricier therapies. Part 1 of 2. Specialty Pharmacy Learning To Love Your Specialty Pharmacy: Perspectives on a New Business RelationshipThe key to a smooth relationship lies in understanding the SP’s capabilities and determining its role in your organization’s success. Clinical A Renewed Emphasis on Therapeutic Angiogenesis Research for CADUp to now, unblocking clogged arteries for so-called no-option patients with coronary artery disease or congestive heart failure hasn’t been possible. Angiogenesis research, despite previous setbacks, may be the answer for this group of patients. DepartmentsOpeners Small Investments, Big PayoffsCould it be this simple? Editorial Choosing the Right ToolDavid B. Nash, MD, MBA, on the four basic tool groups. Washington Watch Traversing the Landscape of Project BioShieldHelp traversing the Valley of Death. Diagnostics and Devices MAYA-II and Molecular ComputingDNA plays games. DrugTrack Approvals, FDA Actions, Clinical TrialsFDA approvals and other actions, plus results of key clinical trials. Biotech Business Phase 4 Research Grows Despite Lack of FDA OversightWho’s pushing postmarketing studies?
Corporate Spotlight Biologics Provide Hope For Immune System DisordersPatients tell the story and ask for appropriate access Trends Specialty Drugs Continue To Drive Spending GrowthSpecialty drugs drive spending growth. |
|||||